Machine learning models can reliably inform clinicians about the disability progression of multiple sclerosis, according to a new study published this week in the open-access journal PLOS Digital ...
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...
12don MSN
Roche says experimental drug helped slow disability in progressive multiple sclerosis study
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.
Breastfeeding for longer in infancy may be associated with lower disease severity and a later onset of MS in adulthood, a ...
—Researchers in Finland concluded that deep cervical lymph node diameter is feasible as a biomarker for multiple sclerosis disease course. An accessible biomarker that tracks disease activity and ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results